Thursday, 5 November 2026European Markets

NEXITY And NEPI ROCKCASTLE Have A High Dividend Yield And Return On Equity In The Real Estate - Diversified Industry.

Loading stream...

(vianews) - nexity (nxi.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate - diversified industry.

financial asset price forward dividend yield return on equity
nexity (nxi.pa) €9.48 27.35% 1.85%
nepi rockcastle (nrp.as) €6.40 7.83% 11.62%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. nexity (nxi.pa)

27.35% forward dividend yield and 1.85% return on equity

nexity sa operates as a real estate company in europe and internationally. the company operates through development, services, and other activities divisions. it develops new homes and subdivisions; and new or refurbished office buildings, high-rises building, business parks, logistics facilities, retail property, hotels, and other industrial spaces. the company also provides property management services comprising rental management, sales and lettings, and condominium managing agent services, as well as manages serviced residences for students; distributes real estate products under the iselection and perl brands; offers insurance brokerage and asset management services; and real estate services, including rental management and property management services, consulting, and short-term rental of working spaces. in addition, it engages in the villes and projets, and pre-development urban regeneration projects; and investment activities. the company serves individual, corporate, institutional, and local authority clients. nexity sa was founded in 1995 and is headquartered in paris, france.

earnings per share

as for profitability, nexity has a trailing twelve months eps of €0.35.

pe ratio

nexity has a trailing twelve months price to earnings ratio of 27.07. meaning, the purchaser of the share is investing €27.07 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.85%.

yearly top and bottom value

nexity's stock is valued at €9.48 at 17:40 est, way below its 52-week high of €24.76 and way higher than its 52-week low of €8.41.

revenue growth

year-on-year quarterly revenue growth declined by 18.8%, now sitting on 3.96b for the twelve trailing months.

more news about nexity.

2. nepi rockcastle (nrp.as)

7.83% forward dividend yield and 11.62% return on equity

nepi rockcastle n.v. (“the company”, “nepi rockcastle”, “the group”) is a public limited company domiciled in the netherlands, having its registered office at strawinskylaan 563, wtc zuidas, tower ten, 5th floor, 1077 xx amsterdam, with registration number at the dutch chamber of commerce 87488329. the company's shares are listed on the main board of the johannesburg stock exchange limited (“jse”), euronext amsterdam and a2x. nepi rockcastle is the premier owner and operator of shopping centres in central and eastern europe (“cee”). the group benefits from a highly-skilled internal management team which combines asset management, development, investment, leasing and financial expertise.

pe ratio

nepi rockcastle has a trailing twelve months price to earnings ratio of 8.53. meaning, the purchaser of the share is investing €8.53 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.62%.

more news about nepi rockcastle.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com